Liu S, Marneth AE, Alexe G, et al. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018;2(23):3428-3442. doi:10.1182/bloodadvances.2018016733.
Benajiba L, Alexe G, Su A, et al. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. Leukemia. 2019;33(3):800-804. doi:10.1038/s41375-018-0291-x.
Ghosh S, Raundhal M, Myers SA, et al. Identification of RIOK2 as a master regulator of human blood cell development. Nat Immunol. 2022;23(1):109-121. doi:10.1038/s41590-021-01079-w.
Guerra RM, Bird GH, Harvey EP, et al. Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep. 2018;24(13):3393-3403.e5. doi:10.1016/j.celrep.2018.08.089.
Tothova Z, Ebert BL. Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell. 2017;168(5):749-750. doi:10.1016/j.cell.2017.02.013.
Cantor JR, Abu-Remaileh M, Kanarek N, et al. Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase. Cell. 2017;169(2):258-272.e17. doi:10.1016/j.cell.2017.03.023.
Mohr S, Doebele C, Comoglio F, et al. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell. 2017;31(4):549-562.e11. doi:10.1016/j.ccell.2017.03.001.
Wagner FF, Benajiba L, Campbell AJ, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10(431). doi:10.1126/scitranslmed.aam8460.
Meyer SE, Muench DE, Rogers AM, et al. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med. 2018;215(8):2115-2136. doi:10.1084/jem.20171312.
Sellar RS, Jaiswal S, Ebert BL. Predicting progression to AML. Nat Med. 2018;24(7):904-906. doi:10.1038/s41591-018-0114-7.